Qli5 Therapeutics
Latest round
- Series A
Last raised
- Jun 2022
Total raised
- $12M
Investors
- 3
About Qli5 Therapeutics
Based in Dortmund, Germany, QLi5 Therapeutics GmbH develops a new class of proteasome inhibitors. The company was co-founded by Prof. Robert Huber and Kiyean Nam. As of 2023, the company is headed by its CEO Martin Huber.14 million post-money. The company offers a proteasome inhibitor platform that can be expanded to various indications as well as has high selectivity and unique, non-covalent binding properties. It has a strong anti-tumor activity against multiple myeloma and solid tumors.
Who invested in Qli5 Therapeutics
3 investors across 2 rounds
See all investors in Qli5 Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Qli5 Therapeutics
Who invested in Qli5 Therapeutics?
Qli5 Therapeutics has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Qli5 Therapeutics raised?
Qli5 Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Qli5 Therapeutics last raise money?
Qli5 Therapeutics's most recent round on record is a Series A, in Jun 2022.
What does Qli5 Therapeutics do?
Based in Dortmund, Germany, QLi5 Therapeutics GmbH develops a new class of proteasome inhibitors.
Where is Qli5 Therapeutics headquartered?
Qli5 Therapeutics is headquartered in Dortmund, Germany.
Which VCs invest in companies like Qli5 Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, Balderton Capital and Sofinnova Partners back healthcare companies at Qli5 Therapeutics's stage. Their profiles are linked below.
VCs backing healthcare startups at Series A
Raising like Qli5 Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.